🇺🇸 MabThera in United States
9,933 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 9,933
Most-reported reactions
- Off Label Use — 2,315 reports (23.31%)
- Pyrexia — 1,425 reports (14.35%)
- Death — 971 reports (9.78%)
- Dyspnoea — 903 reports (9.09%)
- Neutropenia — 895 reports (9.01%)
- Pneumonia — 832 reports (8.38%)
- Disease Progression — 735 reports (7.4%)
- Chills — 648 reports (6.52%)
- Drug Ineffective — 608 reports (6.12%)
- Febrile Neutropenia — 601 reports (6.05%)
Other Oncology, Immunology approved in United States
Frequently asked questions
Is MabThera approved in United States?
MabThera does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for MabThera in United States?
Sandoz is the originator. The local marketing authorisation holder may differ — check the official source linked above.